Yunping Mu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yunping Mu has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Fanghong Li
The International Translational Medical Research Center, Guangdong Engineering Technology Research Center of Metabolic Disorders Interdisciplinary Precision Prevention and Digital Healthcare The Eighth Affiliated Hospital, Southern Medical University Foshan China
11 shared publications - Allan Zijian Zhao
The Eighth Affiliated Hospital, Southern Medical University (The First People’s Hospital of Shunde, Foshan), China
7 shared publications Sujin Zhou
School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong Province, China
6 shared publicationsZhenggang Zhao
School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong Province, China
6 shared publicationsAllan Zijian Zhao
The First People’s Hospital of Shunde, Southern Medical University, Foshan, China
5 shared publicationsWenbin Feng
School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong Province, China
4 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1948763
EPA and DHA engage NRF2 to orchestrate a β-cell resilience circuit suppressing senescence remodeling and sustaining molecular fitness during glucolipotoxic stress
Introduction: Preservation of pancreatic β cells under sustained glucolipotoxicity requires more than limiting cell death, because surviving cells retain stress-associated molecular abnormalities. We tested whether EPA and DHA act through an NRF2-dependent protective program in β-cell models. Methods: MIN6 cells and primary mouse islets were exposed to palmitate plus high glucose with or without EPA, DHA, or EPA+DHA. NRF2 nuclear localization, glutathione homeostasis, oxidative DNA damage, apoptosis, senescence markers, and β-cell maturity proteins were assessed, and NRF2 knockdown was used to test NRF2 dependency. Male C57BL/6J mice with established HFD/STZ diabetes received EPA, DHA, or EPA+DHA; glycemic indices and pancreatic β-cell markers were evaluated. Results: EPA and DHA increased nuclear NRF2, restored glutathione homeostasis, and reduced oxidative DNA damage, apoptotic markers, and senescence markers in both MIN6 cells and primary islets. NRF2 knockdown partially attenuated these responses, indicating that NRF2 contributes to but is not the sole mediator of the in vitro protection. In HFD/STZ mice, EPA/DHA improved glycemic indices, reduced oxidative-stress and apoptotic markers, and preserved insulin-positive β-cell area. Discussion: These findings identify an NRF2-sensitive program through which EPA and DHA preserve antioxidant capacity, survival, and maturity features of β cells under glucolipotoxic stress. Partial attenuation by NRF2 knockdown and the systemic nature of the HFD/STZ model indicate that additional NRF2-independent mechanisms contribute, and that β-cell specific NRF2 deletion will be needed to establish β-cell autonomous causality in vivo .
- 7 October 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1948763
Open AccessEPA and DHA engage NRF2 to orchestrate a β-cell resilience circuit suppressing senescence remodeling and sustaining molecular fitness during glucolipotoxic stress
Introduction: Preservation of pancreatic β cells under sustained glucolipotoxicity requires more than limiting cell death, because surviving cells retain stress-associated molecular abnormalities. We tested whether EPA and DHA act through an NRF2-dependent protective program in β-cell models. Methods: MIN6 cells and primary mouse islets were exposed to palmitate plus high glucose with or without EPA, DHA, or EPA+DHA. NRF2 nuclear localization, glutathione homeostasis, oxidative DNA damage, apoptosis, senescence markers, and β-cell maturity proteins were assessed, and NRF2 knockdown was used to test NRF2 dependency. Male C57BL/6J mice with established HFD/STZ diabetes received EPA, DHA, or EPA+DHA; glycemic indices and pancreatic β-cell markers were evaluated. Results: EPA and DHA increased nuclear NRF2, restored glutathione homeostasis, and reduced oxidative DNA damage, apoptotic markers, and senescence markers in both MIN6 cells and primary islets. NRF2 knockdown partially attenuated these responses, indicating that NRF2 contributes to but is not the sole mediator of the in vitro protection. In HFD/STZ mice, EPA/DHA improved glycemic indices, reduced oxidative-stress and apoptotic markers, and preserved insulin-positive β-cell area. Discussion: These findings identify an NRF2-sensitive program through which EPA and DHA preserve antioxidant capacity, survival, and maturity features of β cells under glucolipotoxic stress. Partial attenuation by NRF2 knockdown and the systemic nature of the HFD/STZ model indicate that additional NRF2-independent mechanisms contribute, and that β-cell specific NRF2 deletion will be needed to establish β-cell autonomous causality in vivo .
- 1 August 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1421, 346059
Bioluminescent enzyme immunoassay for cortisol by exploitation of single-chain variable fragment and single-chain variable fragment-nanoluciferase fusion protein
- 1 August 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1421, 346059
Bioluminescent enzyme immunoassay for cortisol by exploitation of single-chain variable fragment and single-chain variable fragment-nanoluciferase fusion protein
- Open Access
- 3 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Reduced glycoprotein hormone β5 links male aging and testosterone decline to increased adiposity
Aging commonly causes decline of testosterone or estrogen, leading to overaccumulation of fatness in men and women, respectively. Although such a phenomenon can be readily explained by estrogen’s direct action on adipocytes in women, accumulative evidence does not support the direct action of testosterone in adipocyte lipid metabolism, suggesting there is a missing intermediary link. Herein, we propose that glycoprotein hormone β5 (GPHB5) is the intermediary linkage between testosterone and the regulation of adiposity. In clinical samples, blood levels of GPHB5 were correlated negatively with men’s ages and positively with circulating testosterone. Testosterone directly stimulated the expression of GPHB5 in cultured cells; pharmacological blockade of androgen receptor (AR) functions abrogated this effect. Knockout of AR led not only to development of obesity but also reduction of GPHB5 expression. Genetic ablation of GPHB5 in men, but not women, reduced the browning of white adipose tissue, diminished energy expenditure, and caused severe obesity. Importantly, elevated blood testosterone levels did not exert catabolic actions in GPHB5 –/– mice; yet, recombinant GPHB5 protein could stimulate energy expenditure and reduce adiposity. These results provide strong proof that GPHB5 is the “missing” intermediary hormone linking testosterone (and aging) and its well-known catabolic effect on adipose tissue.
- 3 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Open AccessReduced glycoprotein hormone β5 links male aging and testosterone decline to increased adiposity
Aging commonly causes decline of testosterone or estrogen, leading to overaccumulation of fatness in men and women, respectively. Although such a phenomenon can be readily explained by estrogen’s direct action on adipocytes in women, accumulative evidence does not support the direct action of testosterone in adipocyte lipid metabolism, suggesting there is a missing intermediary link. Herein, we propose that glycoprotein hormone β5 (GPHB5) is the intermediary linkage between testosterone and the regulation of adiposity. In clinical samples, blood levels of GPHB5 were correlated negatively with men’s ages and positively with circulating testosterone. Testosterone directly stimulated the expression of GPHB5 in cultured cells; pharmacological blockade of androgen receptor (AR) functions abrogated this effect. Knockout of AR led not only to development of obesity but also reduction of GPHB5 expression. Genetic ablation of GPHB5 in men, but not women, reduced the browning of white adipose tissue, diminished energy expenditure, and caused severe obesity. Importantly, elevated blood testosterone levels did not exert catabolic actions in GPHB5 –/– mice; yet, recombinant GPHB5 protein could stimulate energy expenditure and reduce adiposity. These results provide strong proof that GPHB5 is the “missing” intermediary hormone linking testosterone (and aging) and its well-known catabolic effect on adipose tissue.
- 27 November 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (1) , 265-278
Effect of autophagy-related (Atg) protein 5 on mouse epididymal sperm maturation
Purpose Sperm mature as they transit through the epididymis, during which they gain progressive motility and the capability to fertilize oocytes. Autophagy plays a significant role in the regulation of testicular spermiogenesis. Autophagy-related gene 5 (Atg5) is recognized as a crucial regulator of autophagy progression. However, the role of Atg5 in regulating epididymal sperm maturation has yet to be elucidated. Methods To investigate the function of Atg5 in regulating epididymal sperm maturation, Atg5 conditional knockout mice were generated using Cre/LoxP technology, and sperm quality and fertility were assessed. Comprehensive quantitative analyses and bioinformatics evaluations of the proteome in segments 4–5 of the caput epididymis and sperm from the cauda epididymis were conducted. Results Atg5 deletion reduced autophagy in the caput epididymis but did not significantly affect sperm motility. Quantitative proteomics via data-independent acquisition (DIA) and subsequent bioinformatics analysis revealed significant alterations in the expression of several sperm proteins. Among these, the upregulated proteins were strongly associated with Atg5-independent surrogate autophagy, while the downregulated proteins were linked to sperm maturation. Additionally, qRT-PCR assays demonstrated that seven genes closely related to autophagy and sperm quality were differentially expressed in the 4–5 segments of the caput epididymis. Conclusions Atg5 affects protein expression and abundance in both the caput epididymis (segments 4–5) and cauda epididymal sperm, without statistically significant effects on sperm motility or male fertility. However, the potential impact of autophagy inhibition on sperm maturation may arise under challenging survival conditions by influencing the expression of sperm proteins.
- 27 November 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (1) , 265-278
Effect of autophagy-related (Atg) protein 5 on mouse epididymal sperm maturation
Purpose Sperm mature as they transit through the epididymis, during which they gain progressive motility and the capability to fertilize oocytes. Autophagy plays a significant role in the regulation of testicular spermiogenesis. Autophagy-related gene 5 (Atg5) is recognized as a crucial regulator of autophagy progression. However, the role of Atg5 in regulating epididymal sperm maturation has yet to be elucidated. Methods To investigate the function of Atg5 in regulating epididymal sperm maturation, Atg5 conditional knockout mice were generated using Cre/LoxP technology, and sperm quality and fertility were assessed. Comprehensive quantitative analyses and bioinformatics evaluations of the proteome in segments 4–5 of the caput epididymis and sperm from the cauda epididymis were conducted. Results Atg5 deletion reduced autophagy in the caput epididymis but did not significantly affect sperm motility. Quantitative proteomics via data-independent acquisition (DIA) and subsequent bioinformatics analysis revealed significant alterations in the expression of several sperm proteins. Among these, the upregulated proteins were strongly associated with Atg5-independent surrogate autophagy, while the downregulated proteins were linked to sperm maturation. Additionally, qRT-PCR assays demonstrated that seven genes closely related to autophagy and sperm quality were differentially expressed in the 4–5 segments of the caput epididymis. Conclusions Atg5 affects protein expression and abundance in both the caput epididymis (segments 4–5) and cauda epididymal sperm, without statistically significant effects on sperm motility or male fertility. However, the potential impact of autophagy inhibition on sperm maturation may arise under challenging survival conditions by influencing the expression of sperm proteins.
- 3 October 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 3) , 117388
A novel phosphodiesterase 5 inhibitor, CPD1, alleviates liver fibrosis by modulating the Akt/NF-κB pathway to inhibit activated hepatic stellate cells
- 3 October 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 3) , 117388
A novel phosphodiesterase 5 inhibitor, CPD1, alleviates liver fibrosis by modulating the Akt/NF-κB pathway to inhibit activated hepatic stellate cells
- 24 September 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 3) , 117366
Chronic inhibition of cGMP-specific phosphodiesterase 5 attenuates myocardial hypertrophy by promoting mitophagy in cardiomyocytes
- 24 September 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 3) , 117366
Chronic inhibition of cGMP-specific phosphodiesterase 5 attenuates myocardial hypertrophy by promoting mitophagy in cardiomyocytes
- 9 November 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 282 (Pt 6) , 137457
Omega-3 polyunsaturated fatty acids protect against cisplatin-induced nephrotoxicity by activating the Nrf2 signaling pathway
- 9 November 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 282 (Pt 6) , 137457
Omega-3 polyunsaturated fatty acids protect against cisplatin-induced nephrotoxicity by activating the Nrf2 signaling pathway
- 3 December 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 126, 111299
ω-3 polyunsaturated fatty acid alleviates systemic lupus erythematosus by suppressing autoimmunity in a murine model
- 3 December 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 126, 111299
ω-3 polyunsaturated fatty acid alleviates systemic lupus erythematosus by suppressing autoimmunity in a murine model
- Open Access
- 5 September 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-13
Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease
Background: Fabry disease (FD) is a progressive multisystemic disease characterized by a lysosomal enzyme deficiency. A lack of α-galactosidase A (α-Gal A) activity results in the progressive systemic accumulation of its substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso-Gb3), which results in renal, cardiac, and/or cerebrovascular disease and early death. Enzyme replacement therapy (ERT) is the current standard of care for FD; however, it has important limitations, including a low half-life, limited distribution, and requirement of lifelong biweekly infusions of recombinant enzymes. Methods: Herein, we evaluated a gene therapy approach using an episomal adeno-associated viral 2/8 (AAV2/8) vector that encodes the human GLA cDNA driven by a liver-specific expression cassette in a mouse model of FD that lacks α-Gal A activity and progressively accumulates Gb3 and Lyso-Gb3 in plasma and tissues. Results: A pharmacology and toxicology study showed that administration of AAV2/8-hGLA vectors (AAV2/8-hGLA) in FD mice without immunosuppression resulted in significantly increased plasma and tissue α-Gal A activity and substantially normalized Gb3 and Lyso-Gb3 content. Conclusions: Moreover, the plasma enzymatic activity of α-Gal A continued to be stably expressed for up to 38 weeks and sometimes even longer, indicating that AAV2/8-hGLA is effective in treating FD mice, and that α-Gal A is continuously and highly expressed in the liver, secreted into plasma, and absorbed by various tissues. These findings provide a basis for the clinical development of AAV2/8-hGLA.
- 5 September 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-13
Open AccessSystematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease
Background: Fabry disease (FD) is a progressive multisystemic disease characterized by a lysosomal enzyme deficiency. A lack of α-galactosidase A (α-Gal A) activity results in the progressive systemic accumulation of its substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso-Gb3), which results in renal, cardiac, and/or cerebrovascular disease and early death. Enzyme replacement therapy (ERT) is the current standard of care for FD; however, it has important limitations, including a low half-life, limited distribution, and requirement of lifelong biweekly infusions of recombinant enzymes. Methods: Herein, we evaluated a gene therapy approach using an episomal adeno-associated viral 2/8 (AAV2/8) vector that encodes the human GLA cDNA driven by a liver-specific expression cassette in a mouse model of FD that lacks α-Gal A activity and progressively accumulates Gb3 and Lyso-Gb3 in plasma and tissues. Results: A pharmacology and toxicology study showed that administration of AAV2/8-hGLA vectors (AAV2/8-hGLA) in FD mice without immunosuppression resulted in significantly increased plasma and tissue α-Gal A activity and substantially normalized Gb3 and Lyso-Gb3 content. Conclusions: Moreover, the plasma enzymatic activity of α-Gal A continued to be stably expressed for up to 38 weeks and sometimes even longer, indicating that AAV2/8-hGLA is effective in treating FD mice, and that α-Gal A is continuously and highly expressed in the liver, secreted into plasma, and absorbed by various tissues. These findings provide a basis for the clinical development of AAV2/8-hGLA.
- 29 April 2023
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 24 (2) , 1261-1281
Single-chain variable fragment-based immunoassay for bioactive natural products
- 29 April 2023
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 24 (2) , 1261-1281
Single-chain variable fragment-based immunoassay for bioactive natural products